版本:
中国

BRIEF-Durect and Sandoz signs a $293 mln development and commercialization agreement for Posimir

May 8 Durect Corp:

* Durect and Sandoz have signed a $293 million development and commercialization agreement for Posimir (saber-bupivacaine) covering the United States

* Durect Corp - Durect will remain responsible for completion of ongoing persist phase 3 clinical trial for posimir as well as fda interactions through approval Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐